US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Principal U.S. Small-Cap Multi-Factor ETF

47.51

+0.12000.25%

Post-market: 47.510.00000.00%16:05 EDT

Volume:39.82K

Turnover:1.88M

Market Cap:726.90M

PE:52.79

High:47.52

Open:47.22

Low:46.95

Close:47.39

Loading ...

Overview Company News Filings

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Announces New Medical and Clinical Appointments

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Conrad Asia Energy Unit Signs Settlement Deal with South East Asian Energy Company

MT Newswires Live

Artesian Water Company, Inc. Files Application with Delaware Public Service Commission for Increase in Customer Rates

PSC Corporation Ltd Appoints New Joint Company Secretary

GE2025: Why Singapore's high-flying bureaucrats are recruited into politics

Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC

LIVMARLI Now Approved in Japan for ALGS and PFIC

Is EZCORP Inc. (EZPW) the Best Small-Cap Value Stock to Buy Now?

NuEnergy Gas Shifts Focus to Advanced CBM Projects with Muara Enim 2 PSC Relinquishment

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Commentary: Trump’s mass firings and civil service shake-up - could it happen in Singapore?

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis

Chemomab Therapeutics Reports 2024 Financial Results and Advances PSC Treatment

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

FPL files details of new rate plan designed to power growing state with unmatched combination of high reliability and low bills

AGO Raids Pertamina Patra Niaga's Tanjung Gurem Fuel Terminal

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSC\",,,,,undefined,":{"symbol":"PSC","market":"US","secType":"STK","nameCN":"Principal U.S. Small-Cap Multi-Factor ETF","latestPrice":47.51,"timestamp":1745611200000,"preClose":47.39,"halted":0,"volume":39818,"hourTrading":{"tag":"盘后","latestPrice":47.51,"preClose":47.51,"latestTime":"16:05 EDT","volume":2,"amount":95.02,"timestamp":1745611512925},"delay":0,"floatShares":15300001,"shares":15300001,"eps":0.9,"marketStatus":"Market Closed","change":0.12,"latestTime":"04-25 16:00:00 EDT","open":47.22,"high":47.52,"low":46.95,"amount":1880381.339218,"amplitude":0.012028,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.9,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":47.39,"sharesOutstanding":15320001,"nav":46.559222,"aum":726797464.03,"dividendRate":0.008336,"bidAskSpread":0.002363,"postHourTrading":{"tag":"盘后","latestPrice":47.51,"preClose":47.51,"latestTime":"16:05 EDT","volume":2,"amount":95.02,"timestamp":1745611512925},"volumeRatio":0.251122},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSC\",,,,,undefined,":{"symbol":"PSC","floatShares":15300001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.251122,"shares":15300001,"dividePrice":0.396028,"high":47.52,"amplitude":0.012028,"preClose":47.39,"low":46.95,"week52Low":42.36,"pbRate":"--","week52High":57.24,"institutionHeld":0,"latestPrice":47.51,"eps":0.9,"divideRate":0.008336,"volume":39818,"delay":0,"ttmEps":0.9,"open":47.22,"prevYearClose":51.27,"prevWeekClose":45.92,"prevMonthClose":48.5596,"prevQuarterClose":48.5596,"fiveDayClose":45.92,"twentyDayClose":49.1211,"sixtyDayClose":53.41},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529647669","title":"Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2529647669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529647669?lang=en_us&edition=fundamental","pubTime":"2025-04-24 14:14","pubTimestamp":1745475240,"startTime":"0","endTime":"0","summary":"Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options. Patients treated with elafibranor versus placebo showed significant improvements in liver biochemical parameters, including alkaline phosphatase . Stabilization of non-invasive markers of liver fibrosis were observed in patients on elafibranor versus placebo. PARIS, FRANCE, 24 April 2025 Ipsen  will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver  congress as an oral presentation, on 10 May at 11.15 CET. For the first time data highlighting the potential of elafibranor in treating people living with primary sclerosing cholangitis  will be presented. PSC is a rare liver disease that currently has no approved treatment options.Patients on elafibranor also had stabilization i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breaking-elafibranor-primary-sclerosing-cholangitis-061400283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","LU1242518857.USD","BK4585","BK4007","LU0053671581.USD","LU1559883803.SGD","LU1242518931.SGD","LU1878469433.USD","EC","BK4183","IPSEY","BK4599","IPSEF","GGT","LU0566484027.USD","BK4139","BK4201","PSC","ELF","PBC","BK4588","LU0979878070.USD"],"gpt_icon":0},{"id":"2529806511","title":"Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2529806511","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529806511?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:00","pubTimestamp":1745236800,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, April 21, 2025  -- Chemomab Therapeutics, Ltd., , a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug  for the treatment of patients with primary sclerosing cholangitis  will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology’s annual meeting. Chemomab will report information on the content of the presentations after the meeting embargoes lift.Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients with primary sclerosing cholangitis : The Spring Study. Paul Pockros, MD, Director, Liver Disease Scripps Clinic and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-therapeutics-present-nebokitug-clinical-120000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PSC","BK4007","CMMB","LENZ"],"gpt_icon":0},{"id":"2527490299","title":"Chemomab Announces New Medical and Clinical Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2527490299","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527490299?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience. Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial inPSC, Assumes Chief Development Officer Role. Dr. Weiner commented, “I welcome the opportunity to rejoin Chemomab at this exciting time for the company. We have reported compelling clinical proof-of-concept data showing that nebokitug has the potential to become the first FDA-approved drug for PSC with disease-modifying activity and that it also may have potential in other fibro-inflammatory diseases. These are challenging times for o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-announces-medical-clinical-appointments-120000196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMMB","BK4139","PSC"],"gpt_icon":0},{"id":"2527216355","title":"Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527216355","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527216355?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:30","pubTimestamp":1744633800,"startTime":"0","endTime":"0","summary":"LIVMARLI Tablet formulation approved for patients with Alagille Syndrome  and Progressive Familial Intrahepatic Cholestasis . FOSTER CITY, Calif., April 14, 2025----Mirum Pharmaceuticals, Inc.  today announced that the U.S. Food and Drug Administration  has approved a new tablet formulation of LIVMARLI  for the treatment of cholestatic pruritus in patients with Alagille syndrome  and Progressive Familial Intrahepatic Cholestasis .\"The approval of LIVMARLI in tablet form provides a meaningful additional treatment option for patients with ALGS and PFIC. It allows flexibility for patients and physicians, with the liquid dosing used by the youngest patients and a convenient one-tablet per dose option for older patients,\" said Peter Radovich, president and chief operating officer at Mirum. \"We have had tremendous success with LIVMARLI since its launch and we hope that the availability of the tablet will provide convenience that positively impacts patients’ lives.\". LIVMARLI tablets are plan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-livmarli-now-fda-approved-123000969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALGS","BK4079","BK4588","FSV","MIRM","PSC","BSEP","BK4006","BK4520","BK4516","IBAT","X","BK4532","BK4139","BK4585","BK4505"],"gpt_icon":0},{"id":"2526378509","title":"Conrad Asia Energy Unit Signs Settlement Deal with South East Asian Energy Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2526378509","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526378509?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:56","pubTimestamp":1744250178,"startTime":"0","endTime":"0","summary":"Conrad Asia Energy,  its subsidiary, and West Natuna Exploration , operator of Duyung Production Sharing Contract , signed a settlement agreement with Coro Energy and Coro Energy Duyung , according to a Thursday filing with the Australian bourse.The agreement outlines the transfer of Coro Duyung's 15% participating interest in the Duyung PSC to WNEL, bringing WNEL's total interest to 91.5%, the filing said.Coro Duyung is also released from any obligation to pay cash calls, and WNEL will receive a total cash consideration of $300,000 from Coro Energy.The agreement is contingent on approval from Indonesia's Ministry of Energy and Mineral Resources and shareholder approval, per the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7142","PSC","BK7095","BK6053","PSC.AU","DM0.SI","CRD.AU"],"gpt_icon":0},{"id":"2525737496","title":"Artesian Water Company, Inc. Files Application with Delaware Public Service Commission for Increase in Customer Rates","url":"https://stock-news.laohu8.com/highlight/detail?id=2525737496","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525737496?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:05","pubTimestamp":1743797100,"startTime":"0","endTime":"0","summary":"NEWARK, Del., April  04, 2025  (GLOBE NEWSWIRE) -- Artesian Water Company, Inc. (“Artesian”), a subsidiary of Artesian Resources Corporation (Nasdaq: ARTNA), filed an application with the Delaware Pub","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3056193/30413/en/Artesian-Water-Company-Inc-Files-Application-with-Delaware-Public-Service-Commission-for-Increase-in-Customer-Rates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSC"],"gpt_icon":0},{"id":"2524919565","title":"PSC Corporation Ltd Appoints New Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2524919565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524919565?lang=en_us&edition=fundamental","pubTime":"2025-04-01 17:43","pubTimestamp":1743500594,"startTime":"0","endTime":"0","summary":"The latest announcement is out from PSC Corporation Ltd ( ($SG:DM0) ). PSC Corporation Ltd has announced the appointment of Ms. Siau Kuei Lian as J...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/psc-corporation-ltd-appoints-new-joint-company-secretary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/psc-corporation-ltd-appoints-new-joint-company-secretary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4185","BK4209","JYNT","SG","PSC"],"gpt_icon":0},{"id":"2522526805","title":"GE2025: Why Singapore's high-flying bureaucrats are recruited into politics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522526805","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522526805?lang=en_us&edition=fundamental","pubTime":"2025-03-28 06:00","pubTimestamp":1743112800,"startTime":"0","endTime":"0","summary":"In recent weeks, top ministry officials have resigned, fuelling speculation they could be fielded as potential candidates for the ruling People's Action Party in the 2025 General Election.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--P9fINhag--/c_crop,h_900,w_1600,x_0,y_0/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/27/civil-servants-politics-hero.png?itok=zaq0mQYL","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--P9fINhag--/c_crop,h_900,w_1600,x_0,y_0/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/27/civil-servants-politics-hero.png?itok=zaq0mQYL"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/ge2025-civil-servants-public-service-politics-candidates-pap-5015676","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["GE","LU1064131342.USD","LU0149725797.USD","LU1366333091.USD","LU0157215616.USD","BK4501","BK4187","LU0868494617.USD","BK4566","LU2756315664.SGD","BK4588","LU0689472784.USD","LU0820561818.USD","LU1093756325.SGD","LU2756315318.SGD","BK6053","BK4543","LU0354030511.USD","LU1261432733.SGD","LU0354030438.USD","MP","LU0943347566.SGD","LU1988902786.USD","BK4585","LU0820562030.AUD","LU1551013342.USD","BK4206","PSC","DM0.SI","BK4168","LU0640476718.USD","LU0820561909.HKD","LU2264538146.SGD","LU2543165471.USD","LU1551013425.SGD","IE00BD6J9T35.USD","LU1280957306.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2522303719","title":"Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC","url":"https://stock-news.laohu8.com/highlight/detail?id=2522303719","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522303719?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:57","pubTimestamp":1743080251,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics ( ($CMMB) ) has shared an update. On March 27, 2025, Chemomab Therapeutics announced positive results from the Open Label Ext...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chemomabs-nebokitug-shows-promising-phase-2-results-for-psc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chemomabs-nebokitug-shows-promising-phase-2-results-for-psc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSC"],"gpt_icon":0},{"id":"2522301581","title":"LIVMARLI Now Approved in Japan for ALGS and PFIC","url":"https://stock-news.laohu8.com/highlight/detail?id=2522301581","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522301581?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:30","pubTimestamp":1743078600,"startTime":"0","endTime":"0","summary":"- LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan. FOSTER CITY, Calif., March 27, 2025----Mirum Pharmaceuticals, Inc.  today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI  oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome  and Progressive Familial Intrahepatic Cholestasis  in Japan.\"We are thrilled to see LIVMARLI approved as the first and only medication available in Japan for patients living with pruritus related to ALGS and PFIC,\" said Chris Peetz, chief executive officer at Mirum. \"Takeda is a leading global pharmaceutical company with demonstrated success in the development and commercialization of medicines for rare diseases. Under Takeda’s leadership, we are confident that LIVMARLI could have a meaningful imp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/livmarli-now-approved-japan-algs-123000577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4588","BSEP","BK4079","BK4532","FSV","ALGS","X","MIRM","PSC","BK4516","BK4520","IBAT","BK4139","BK4006","BK4585"],"gpt_icon":0},{"id":"2521720769","title":"Is EZCORP Inc. (EZPW) the Best Small-Cap Value Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521720769","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521720769?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:15","pubTimestamp":1742822122,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Small-Cap Value Stocks to Buy Now. In this article, we are going to take a look at where EZCORP Inc.  stands against other best small-cap value stocks to buy now.Earlier on February 24, Robert Teeter of Silvercrest Asset Management shared his perspective on small-cap stocks and highlighted their link to economic conditions and sensitivity to financing activity. He noted that the Trump trade initially boosted small caps due to expectations of economic acceleration and lower interest rates, both of which are favorable for these companies. However, policy uncertainty and weaker-than-expected economic data have delayed their rally. Teeter believes that small caps will come into their own later in the year, but for now, they are facing a choppy market with significant rotation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ezcorp-inc-ezpw-best-small-131522645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","TSYW.SI","PSC","PSQ","USAW.SI","EZPW","MNQmain","TQQQ",".IXIC","USJW.SI","NVIW.SI","BK4166","NQmain","SQQQ","QID"],"gpt_icon":1},{"id":"2518763253","title":"NuEnergy Gas Shifts Focus to Advanced CBM Projects with Muara Enim 2 PSC Relinquishment","url":"https://stock-news.laohu8.com/highlight/detail?id=2518763253","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518763253?lang=en_us&edition=fundamental","pubTime":"2025-03-11 13:19","pubTimestamp":1741670384,"startTime":"0","endTime":"0","summary":"NuEnergy Gas Limited ( ($AU:NGY) ) has shared an announcement. NuEnergy Gas Limited has announced the relinquishment of its 30% interest in the Mua...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nuenergy-gas-shifts-focus-to-advanced-cbm-projects-with-muara-enim-2-psc-relinquishment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nuenergy-gas-shifts-focus-to-advanced-cbm-projects-with-muara-enim-2-psc-relinquishment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZL793.SGD","AEIS","IE0031619046.USD","PSC","IE00B19Z4B17.USD","BK4157","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2518367087","title":"Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518367087","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518367087?lang=en_us&edition=fundamental","pubTime":"2025-03-11 08:00","pubTimestamp":1741651200,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., March 11, 2025----Mirum Pharmaceuticals, Inc.  today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 17,620 shares of common stock and 9,290 restricted stock units  to five new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635.Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI  oral solution, CHOLBAM  capsules, and CTEXLI  tablets.Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-pharmaceuticals-reports-inducement-grants-000000746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRM","SQQQ","BK4006",".IXIC","MNQmain","BK4139","USAW.SI","X","LU2095319765.USD","BK4585","QLD","BK4588","IE00B64PRP62.GBP","NDAQ","NVIW.SI","IE00B3QW5Z07.USD","LU2210149790.SGD","TSYW.SI","IE00BKPKM429.USD","QID","BK4516","NQmain","PSC","TQQQ","BK4520","IE00BGHQF748.EUR","LU2210150020.SGD","USJW.SI","PSQ","BK4112"],"gpt_icon":1},{"id":"2518215735","title":"Commentary: Trump’s mass firings and civil service shake-up - could it happen in Singapore?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518215735","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518215735?lang=en_us&edition=fundamental","pubTime":"2025-03-11 06:00","pubTimestamp":1741644000,"startTime":"0","endTime":"0","summary":"While our context is very different, Singapore must strive to keep public sector growth sustainable, says SUSS’s Terence Ho.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--WfsuXLQ5--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/07/istock-1950678152.jpg?itok=gMP_xS_R","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--WfsuXLQ5--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/03/07/istock-1950678152.jpg?itok=gMP_xS_R"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/commentary/trump-musk-doge-federal-job-cuts-government-employees-departments-closed-usaid-4984916","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["PSC"],"gpt_icon":0},{"id":"2517154084","title":"New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517154084","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517154084?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:00","pubTimestamp":1741266000,"startTime":"0","endTime":"0","summary":"Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Featuresof Systemic Sclerosis TEL AVIV, Israel, March  06, 2025  (GLOBE NEWSWIRE) -- Chemomab Therapeutics,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038138/0/en/New-Data-Presented-at-CORA-2025-Conference-Highlights-Clinical-Potential-of-Chemomab-s-Nebokitug-in-Systemic-Sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","LU1559883803.SGD","PSC","ELF","LU1242518857.USD","LU0053671581.USD","BK4585","BK4588","LU1242518931.SGD","BK4183","LU0566484027.USD"],"gpt_icon":0},{"id":"2516897636","title":"Chemomab Therapeutics Reports 2024 Financial Results and Advances PSC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516897636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516897636?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:29","pubTimestamp":1741008546,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Chemomab Therapeutics ( ($CMMB) ). Chemomab Therapeutics announced its year-end and fourth-quarter 2024 financi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chemomab-therapeutics-reports-2024-financial-results-and-advances-psc-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chemomab-therapeutics-reports-2024-financial-results-and-advances-psc-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","PSC"],"gpt_icon":0},{"id":"2516635884","title":"Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635884","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635884?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035549/0/en/Chemomab-Therapeutics-Announces-Year-End-and-Fourth-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","BK4218","LU1559883803.SGD","PSC","ELF","INN","LU1242518857.USD","LU0053671581.USD","BK4585","BK4588","BK4181","LU0566484027.USD","LU1242518931.SGD","BK4183","LENZ","BK4139"],"gpt_icon":0},{"id":"2514732240","title":"FPL files details of new rate plan designed to power growing state with unmatched combination of high reliability and low bills","url":"https://stock-news.laohu8.com/highlight/detail?id=2514732240","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514732240?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:45","pubTimestamp":1740750300,"startTime":"0","endTime":"0","summary":"JUNO BEACH, Fla., Feb. 28, 2025 /PRNewswire/ -- Florida Power & Light Company today submitted a comprehensive four-year request to the Florida Public Service Commission  to set new rates once its current base rate agreement concludes at the end of this year.The proposal, covering 2026 through 2029, would enable FPL to continue to deliver some of the nation's most reliable electricity, provide excellent customer service, diversify its generation resources to reduce fuel costs, and keep bills as low as possible.A word from FPL President and CEO Armando Pimentel: \"At FPL, we're focused on our customers every single day. The balanced plan we submitted to the PSC would enable FPL to continue to make smart investments in the grid and in new generation resources to benefit our customers and to power our fast-growing state. No other utility in the U.S. provides a better combination of reliability, resiliency and low bills than FPL.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fpl-files-details-rate-plan-134500596.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fpl-files-details-rate-plan-134500596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","LU0057025933.USD","LU0175139822.USD","IE00BMG7P694.USD","BK4606","IE00B29SXK94.USD","LU1084165304.USD","LU2023250843.SGD","LU2048586759.USD","LU0289961442.SGD","LU0289739343.SGD","LU2384288077.EUR","IE00BMG7P926.USD","LU2462611646.USD","LU2264538146.SGD","LU1366192091.USD","IE00BMG7P702.HKD","IE00B3CCJ633.GBP","LU1929549753.HKD","BK4588","LU1064131342.USD","NEE","LU1621767737.EUR","IE00BMG7P819.SGD","LU2275660780.HKD","LU2211814178.USD","LU2637428348.USD","LU0786609619.USD","BK4581","PSC","LU2244417387.USD","IE00BMG7P587.USD","LU0689626769.HKD","LU1621768206.USD","IE00BJTD4N35.SGD","LU1939255532.USD","LU1621768115.EUR","LU2498475776.HKD","LU0289960550.SGD","BK4566","IE00B2PGVK34.USD","FPL","LU2298322129.HKD","BK4533","BK4597","IE00BJTD4V19.USD","LU1988902786.USD","LU2023250504.SGD","IE00BGHQF417.EUR","LU1093756325.SGD"],"gpt_icon":0},{"id":"2516537120","title":"AGO Raids Pertamina Patra Niaga's Tanjung Gurem Fuel Terminal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516537120","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516537120?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:51","pubTimestamp":1740739878,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -The Attorney General's Office  is conducting a raid at the Tanjung Gurem Fuel Terminal office in Grogol District, Cilegon, Banten. Based on Google Maps, the address corresponds to a fuel terminal owned by Pertamina Patra Niaga.“The raid has been underway since 10:30 a.m.,” said Harli Siregar, head of the AGO’s Legal Information Center, on February 28.The operation is part of an ongoing investigation into alleged corruption in the management of crude oil and refinery products at PT Pertamina, its sub-holdings, and Production Sharing Contract  contractors from 2018 to 2023.","market":"nz","thumbnail":"https://statik.tempo.co/data/2025/02/27/id_1380677/1380677_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/02/27/id_1380677/1380677_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1981028/ago-raids-pertamina-patra-niagas-tanjung-gurem-fuel-terminal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK7095","AGO","PSC","PSC.AU","BK4107","BK4166","PT"],"gpt_icon":0},{"id":"2514898508","title":"Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898508","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898508?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":"- 2025 expected global net product sales of $420 million to $435 million. - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026. - CTEXLI  approved in the US for cerebrotendinous xanthomatosis. - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET. FOSTER CITY, Calif., February 26, 2025----Mirum Pharmaceuticals, Inc.  today reported financial results for the fourth quarter and year-end 2024 and provided a business update.\"2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue,\" said Chris Peetz, chief executive officer of Mirum. \"We continue to expand the reach of our three commercial medicines within our patient communities and look forward to another year of strong financial performance. On top of this, we are looking forward to multiple upcoming clinical and regulatory milestones, such as PSC where we’re expecting ful","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-pharmaceuticals-reports-fourth-quarter-210100952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBAT","BK4520","BK4139","X","ALGS","BK4588","GGT","BK4516","BK4585","BK4599","BK4505","BK4532","BK4006","FSV","BK4079","PBC","PSC","ALT","MIRM","LU1878469433.USD","FXS","BSEP"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSC\",params:#limit:5,,,undefined,":[{"date":"2025-04-01","symbol":"PSC","amount":0.110318,"announcedDate":"2025-01-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-03"},{"date":"2024-12-27","symbol":"PSC","amount":0.07952,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2024-12-31"},{"date":"2024-10-01","symbol":"PSC","amount":0.1071,"announcedDate":"2024-09-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-10-01","defaultRemindTime":1727789400000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-03","payableDate":"2024-10-01","currency":"USD","dateTimestamp":1727755200000,"payDate":"2024-10-03"},{"date":"2024-07-01","symbol":"PSC","amount":0.09909,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-07-01","name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-03","payableDate":"2024-07-01","currency":"USD","dateTimestamp":1719806400000,"payDate":"2024-07-03"},{"date":"2024-04-01","symbol":"PSC","amount":0.096411,"announcedDate":"2024-03-28","type":"dividend","market":"US","newRecordDate":"2024-04-02","defaultRemindTime":1711978200000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","recordDate":"2024-04-04","payableDate":"2024-04-02","currency":"USD","dateTimestamp":1711944000000,"payDate":"2024-04-04"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSC\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-04","value":0.0954808,"currency":"USD"},{"executeDate":"2017-04-03","recordDate":"2017-04-05","paymentDate":"2017-04-07","value":0.073752,"currency":"USD"},{"executeDate":"2017-07-03","recordDate":"2017-07-06","paymentDate":"2017-07-10","value":0.078723,"currency":"USD"},{"executeDate":"2017-10-02","recordDate":"2017-10-03","paymentDate":"2017-10-05","value":0.053592,"currency":"USD"},{"executeDate":"2018-04-02","recordDate":"2018-04-03","paymentDate":"2018-04-05","value":0.083439,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSC\",market:\"US\",delay:false,,,undefined,":{}}}